IBN Unveils New Episode of The BioMedWire Podcast with CNS Pharmaceuticals Inc. CEO John Climaco

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Aug 27 2025

0mins

CNSP-5.32%

Should l Buy CNSP?

Source: Newsfilter

Podcast Release: IBN has released a new episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals, discussing advancements in treatments for brain cancer.
CNS Pharmaceuticals Focus: The company is dedicated to developing novel therapies for glioblastoma and other cancers that affect the brain and central nervous system, addressing significant unmet medical needs.
Drug Development Strategy: CNS Pharmaceuticals has successfully pivoted from its berubicin study to focus on TPI 287, demonstrating resilience in drug development despite high failure rates in oncology trials.
Market Potential: Climaco highlighted the vast opportunities for their drugs in various cancer markets, emphasizing the company's operational expertise and commitment to advancing treatment options for patients.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy CNSP?" and start using high-conviction signals backed by rigorous historical data.

CNSP

$4.27+Infinity%1D

Analyst Views on CNSP

Wall Street analysts forecast CNSP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CNSP is 20.00 USD with a low forecast of 20.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Analyst Rating

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.510

Low

20.00

Averages

20.00

High

20.00

Current: 4.510

Low

20.00

Averages

20.00

High

20.00

UBS

Neutral

maintain

$63 -> $66

2026-01-08

Reason

UBS

Price Target

$63 -> $66

AI Analysis

2026-01-08

maintain

Neutral

Reason

UBS raised the firm's price target on Centerspace to $66 from $63 and keeps a Neutral rating on the shares. 2026 is expected to mark a pivotal REIT turnaround, with forecast total returns of 9%-11% driven by improving macro conditions, attractive valuations, easing supply pressures, and a more stable political backdrop, the analyst tells investors in a research note. The outlook points to a bifurcated year with defensiveness in the first half of 2026 and stronger catalysts in the second half, favoring Healthcare, Shopping Centers, and Coastal Apartments, UBS says.

Cantor Fitzgerald

Richard Anderson

Neutral

maintain

$62 -> $65

2026-01-05

Reason

Cantor Fitzgerald

Richard Anderson

Price Target

$62 -> $65

2026-01-05

maintain

Neutral

Reason

Cantor Fitzgerald analyst Richard Anderson raised the firm's price target on Centerspace to $65 from $62 and keeps a Neutral rating on the shares. U.S. equity REITs returned 2.9% in 2025, lagging the S&P 500, but 2026 may offer optimism with a potentially more supportive macro environment and an accelerating M&A theme, the analyst tells investors in a research note. Stable supply and demand fundamentals, balance sheet strength, and a well-covered, growing 4% dividend yield make the sector attractive despite past underperformance, Cantor adds.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CNSP

Unlock Now

About CNSP

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Webtoon Entertainment Shares Surge 48%; Check Out 20 Stocks Making Moves in Premarket Trading

Sep 16 2025Benzinga

Webtoon Entertainment Partnership: Webtoon Entertainment Inc's shares surged 47.8% in pre-market trading after announcing a partnership with The Walt Disney Co to create a digital comics platform featuring Marvel, Star Wars, Pixar, and Disney titles.
Pre-Market Stock Movements: Several stocks experienced significant pre-market trading changes, with FGI Industries Ltd gaining 185.2% and Conifer Holdings Inc rising 136.8%, while Apartment Investment and Management Company saw a decline of 9.4%.

CNS Pharmaceuticals Receives Buy Rating from Maxim Following TPI-287 Development Plan

Sep 13 2025Yahoo Finance

CNS Pharmaceuticals Upgrade: Maxim upgraded CNS Pharmaceuticals from Hold to Buy with a price target of $20, highlighting the company's focus on its oncology asset TPI-287 for treating recurrent glioblastoma.
Financial Outlook: The analyst noted CNS Pharmaceuticals' roadmap for TPI-287, potential developments with Berubicin, and a cash runway extending into the second half of 2026, indicating a positive outlook for the stock's recovery.